A. Barbato

A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in adults: One-year results.

C. Hollak, R. Lachmann, T. Ikezoe, 2022, Genetics in medicine : official journal of the American College of Medical Genetics.

Similarities and differences between Gaucher disease and acid sphingomyelinase deficiency: An algorithm to support the diagnosis.

M. Cappellini, F. Giona, F. Carubbi, 2022, European journal of internal medicine.

Overexpression of Cell Cycle Progression Inhibitor Geminin is Associated with Tumor Stem-Like Phenotype of Triple-Negative Breast Cancer

G. Botti, M. Cantile, G. Liguori, 2012, Journal of breast cancer.

Acid sphingomyelinase deficiency (ASMD): addressing knowledge gaps in unmet needs and patient journey in Italy—a Delphi consensus

G. Trifirò, M. Cappellini, A. Pession, 2023, Internal and Emergency Medicine.

Improving assessment and management of large non-pedunculated colorectal lesions in a Western center over 10 years: lessons learned and clinical impact

S. Angeletti, E. di Giulio, G. Vanella, 2020, Endoscopy International Open.

Continued improvement in disease manifestations of acid sphingomyelinase deficiency for adults with up to 2 years of olipudase alfa treatment: open-label extension of the ASCEND trial

B. Thurberg, J. Hennermann, P. Mabe, 2023, Orphanet Journal of Rare Diseases.